Drug intelligence / Profile preview

18F-7-fluoro-L-tryptophan

Lead developer
Universitätsklinikum Köln
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

18F-7-fluoro-L-tryptophan (7-[18F]FTrp) is a fluorine-18 labeled radiopharmaceutical and positron emission tomography (PET) imaging agent designed to visualize and monitor tryptophan metabolism in vivo. Developed by researchers at the University Clinic of Cologne and Forschungszentrum Jülich, this tracer is highly stable in vivo, unlike other fluorinated tryptophan derivatives that undergo rapid defluorination. It is transported into cells via amino acid transporters (such as LAT1) and can be used to image brain tryptophan metabolism (including serotonin and melatonin synthesis) as well as peripheral tryptophan catabolism via the kynurenine pathway, which is often dysregulated in neurodegenerative diseases (like Parkinson's disease) and various cancers (such as prostate cancer).

Other names
18F-7-F-Trp18F-7-fluoro-tryptophan7-[18F]F-Trp7-[18F]FTrp7-[18F]fluoro-L-tryptophan7-[18F]fluorotryptophan
02

Identity

Drug type
Radiopharmaceuticals
Originator
Forschungszentrum Jülich GmbH and University Hospital Cologne
Modality
Small MoleculesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesPositron Emitters
03

Pharmacology

04

Development

IndicationHighest phaseStatus
Lewy body disease spectrum (LBD)PreclinicalActive
Parkinson's disease (PD)PreclinicalActive
prostate cancer and precursor lesionsPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Forschungszentrum Jülich GmbH and University Hospital CologneOriginator
  • Universitätsklinikum KölnLead developer
07

Competitive landscape

Drugs on the same target
20
Drugs in the lead indication
38

Lead indication: Lewy body disease spectrum (LBD)

Most advanced in the lead indication

  1. floretyrosine (18F)Approved
  2. fluciclovine f 18Approved
  3. O-(2-[18F]fluoroethyl)-L-tyrosineApproved
  4. citicolinePhase 4
  5. dapagliflozinPhase 4

Beyond the preview

Go deeper on 18F-7-fluoro-L-tryptophan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-7-fluoro-L-tryptophan.

Work on 18F-7-fluoro-L-tryptophan? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call